BioCentury
ARTICLE | Company News

Adlai Nortye gets rights to buparlisib from Novartis

July 13, 2018 7:57 PM UTC

Adlai Nortye Biopharma Co. Ltd. (Hangzhou, China) gained exclusive, worldwide rights to cancer candidate buparlisib (BKM120) from Novartis AG (NYSE:NVS; SIX:NOVN). Financial terms were not disclosed.

Adlai Nortye has global rights to develop and commercialize buparlisib, except for "certain limited rights" Novartis retained "to comply with ongoing contractual obligations," Novartis spokesperson Eric Althoff told BioCentury. Althoff declined to provide details...

BCIQ Company Profiles

Adlai Nortye Ltd.

Novartis AG